Huang Shiu-Feng, Chen Ya-Ting, Lee Wei-Chen, Chang Il-Chi, Chiu Yu-Ting, Chang Yu, Tu Hsiao-Chen, Yuh Chiou-Hwa, Matsuura Isao, Shih Liang-Yu, Lai Ming-Wei, Wu Hong-Dar Isaac, Chen Miin-Fu, Yeh Chau-Ting
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan ; Department of Pathology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan ; Department of Pathology, Tzu-Chi General Hospital, Taipei Branch, Tzu-Chi University School of Medicine, Hualien, Taiwan.
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
PLoS One. 2014 Feb 24;9(2):e89753. doi: 10.1371/journal.pone.0089753. eCollection 2014.
BACKGROUND & AIMS: The correlation between chronic hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) has been well-established. But the roles of viral factor remain uncertain. Only HBV X gene and nonsense mutations of S gene (C-terminal truncation of HBV surface protein) have been demonstrated to have transforming activity. Whether they play a significant role in hepatocarcinogenesis is still uncertain.
Twenty-five HBV-related HCC patients were positive for hepatitis B core antigen (HBcAg) in the cancerous parts of their HCC liver tissues by immunohistochemistry studies, and had available tissue for whole HBV genome sequence analysis. The results were compared with 25 gender and age-matched HBcAg negative HCCs. Plasmids encoding HBV S gene nonsense mutations identified from HBcAg (+) HCC tissue were constructed to investigate their cell proliferation, transformation activity and the oncogenic potentials by xenograft study and in vivo migration assay.
HBcAg (+) HCC patients were significantly associated with cirrhosis and small tumor size (≦2 cm) when compared with HBcAg (-) HCC patients. Southern blot analyses revealed freely replicative forms of HBV in the cancerous parts of HBcAg(+) HCC. Three nonsense mutations of S gene (sL95*, sW182*, and sL216*) were identified in the HBcAg(+) HCC tumor tissues. sW182* and sL216* were recurrently found in the 25 HBcAg (-) HCC tumor tissue, too. Functional studies of the above 3 non-sense mutations all demonstrated higher cell proliferation activities and transformation abilities than wild type S, especially sW182*. Tumorigenicity analysis by xenograft experiments and in vitro migration assay showed potent oncogenic activity of sW182* mutant.
This study has demonstrated potent oncogenic activity of nonsense mutations of HBV S gene, suggesting they may play an important role in hepatocarcinogenesis.
慢性乙型肝炎病毒(HBV)感染与肝细胞癌(HCC)之间的相关性已得到充分证实。但病毒因素的作用仍不确定。仅HBV X基因和S基因的无义突变(HBV表面蛋白C末端截短)已被证明具有转化活性。它们在肝癌发生中是否起重要作用仍不确定。
通过免疫组织化学研究,25例HBV相关肝癌患者的肝癌肝组织癌灶部分乙型肝炎核心抗原(HBcAg)呈阳性,且有可用组织进行全HBV基因组序列分析。将结果与25例性别和年龄匹配的HBcAg阴性肝癌患者进行比较。构建从HBcAg(+)肝癌组织中鉴定出的编码HBV S基因无义突变的质粒,通过异种移植研究和体内迁移试验研究其细胞增殖、转化活性和致癌潜力。
与HBcAg(-)肝癌患者相比,HBcAg(+)肝癌患者与肝硬化和小肿瘤大小(≤2 cm)显著相关。Southern印迹分析显示HBcAg(+)肝癌癌灶部分存在自由复制形式的HBV。在HBcAg(+)肝癌肿瘤组织中鉴定出S基因的三个无义突变(sL95*、sW182和sL216)。sW182和sL216在25例HBcAg(-)肝癌肿瘤组织中也反复出现。上述3种无义突变的功能研究均显示出比野生型S更高的细胞增殖活性和转化能力,尤其是sW182*。通过异种移植实验和体外迁移试验进行的致瘤性分析显示sW182*突变体具有强大的致癌活性。
本研究证明了HBV S基因无义突变具有强大的致癌活性,表明它们可能在肝癌发生中起重要作用。